目的 探討胃蘇顆粒聯(lián)合美沙拉嗪治療腸易激綜合征的臨床效果。方法 選取2016年6月-2019年6月鄭州市第九人民醫(yī)院收治的104例腸易激綜合征患者，隨機分成對照組和治療組，每組各52例。對照組患者口服美沙拉嗪腸溶片，0.5 g/次，3次/d，餐后整片吞服。治療組在對照組基礎(chǔ)上口服胃蘇顆粒，1袋/次，3次/d，適量開水沖服。兩組均連續(xù)治療4周。觀察兩組臨床療效，比較兩組治療前后腸易激綜合征-癥狀嚴(yán)重程度量表（IBS-SSS）評分、匹茲堡睡眠質(zhì)量指數(shù)（PSQI）評分、腸易激綜合征-生活質(zhì)量量表（IBS-QOL）評分和相關(guān)血清學(xué)指標(biāo)的變化情況。結(jié)果 治療組總有效率94.2%較對照組80.8%顯著提高（P<0.05）。兩組治療后IBS-SSS中各項（腹脹程度、腹痛程度、腹痛頻率等）評分及其總分均顯著低于治療前（P<0.05）；但治療組下降更顯著（P<0.05）。與治療前相比，兩組治療后PSQI總分均顯著降低（P<0.05），而IBS-QOL總分均顯著增高（P<0.05）；且治療后，治療組患者PSQI總分顯著低于對照組同期（P<0.05），IBS-QOL總分則顯著更高（P<0.05）。治療后兩組患者血清腫瘤壞死因子（TNF）-α、白介素（IL）-1β、IL-6、丙二醛（MDA）水平均顯著低于治療前（P<0.05）；且治療組治療后以上血清學(xué)指標(biāo)水平均較對照組同期顯著更低（P<0.05）。結(jié)論 胃蘇顆粒聯(lián)合美沙拉嗪治療腸易激綜合征的整體療效良好，可明顯改善患者癥狀，緩解腸黏膜低度炎癥狀態(tài)，降低氧化應(yīng)激損傷，提高患者睡眠質(zhì)量及生命質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Weisu granules combined with mesalazine in treatment of irritable bowel syndrome. Methods 104 Patients with irritable bowel syndrome admitted to Ninth People's Hospital of Zhengzhou from June 2016 to June 2019 were randomly divided into treatment group (n=52) and control group (n=52). The control group was po administered with Mesalazine Enteric-coated Tablets swallow whole piece after meal, 0.5 g/time, three times daily. The treatment group was po administered with Weisu Granules on the basis of the control group, 1 bag/time, three times daily. All patients were treated for 4 weeks. The clinical efficacy of the two groups was observed, and the changes in irritable bowel syndrome-Symptom Severity Scale (IBS-SSS) score, Pittsburgh Sleep Quality Index (PSQI) score, Irritable bowel syndrome-Quality of Life Scale (IBS-QOL) score and related serological indicators before and after treatment were compared between the two groups. Results The total effective rate of 94.2% in the treatment group was significantly higher than 80.8% in the control group (P<0.05). After treatment, all the scores (degree of abdominal distension, degree of abdominal pain, frequency of abdominal pain, etc.) in IBS-SSS and their total scores were significantly lower than those before treatment (P<0.05). However, the reduction was more significant in the treatment group (P<0.05). Compared with before treatment, the total score of PSQI in both groups was significantly reduced after treatment (P<0.05), but the total score of IBS-QOL was significantly increased (P<0.05). After treatment, the total score of PSQI in the treatment group was significantly lower than that in the control group (P<0.05), and the total score of IBS-QOL was significantly higher (P<0.05). The serum levels of TNF-α, IL-1β, IL-6, and MDA in both groups were significantly lower than those before treatment (P<0.05). The serological indexes of the treatment group were significantly lower than those of the control group (P<0.05). Conclusion Weisu Granules combined with mesalazine has overall efficacy in treatment of irritable bowel syndrome, and can significantly improve the symptoms of patients, and also can relieve low-grade inflammation of intestinal mucosa, and reduce oxidative stress injury, improve the quality of sleep and life, which has a certain clinical application value.

R975

河南省科技攻關(guān)計劃項目（162102310287）